EXSCIENTIA
7.9.2022 14:01:41 CEST | Business Wire | Press release
Exscientia (Nasdaq: EXAI) today announced that Company management will participate in the following investor conferences in September:
Morgan Stanley Annual Global Healthcare Conference:
Date: Wednesday, September 14, 2022
Time: 3:35 p.m. BST / 10:35 a.m. EST
Location: New York, New York
Participants: Ben Taylor, CFO & Chief Strategy Officer and Dave Hallett, Chief Operations Officer
BofA Securities Global Healthcare Conference:
Date: Thursday, September 15, 2022
Time: 3:05 p.m. BST / 10:05 a.m. EST
Location: London, United Kingdom
Participants: Andrew Hopkins, DPhil., Exscientia’s founder and CEO, and Garry Pairaudeau, Chief Technology Officer
Live webcasts of the presentations will be available on the Company’s website, under the “Investors & Media” section at www.investors.exscientia.ai. Archived replays of the webcasts will be available for approximately 30 days following the presentation.
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.
Exscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).
Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005300/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gurobi Appoints Dr. Pascal Van Hentenryck to Lead AI Innovation Lab17.2.2026 15:00:00 CET | Press release
Renowned optimization and AI technologies leader to advance hybrid approaches for demanding decision challenges. Gurobi Optimization, LLC, the leader in decision intelligence technology, is pleased to announce that Dr. Pascal Van Hentenryck has joined the company as head of the Gurobi AI Innovation Lab (GAIL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217170385/en/ Dr. Pascal Van Hentenryck, Head of AI Innovation Lab, Gurobi Optimization As part of Gurobi’s long-term product and technology strategy, the Gurobi AI Innovation Lab is a focused Research & Development initiative dedicated to advancing the combination of multiple AI technologies with optimization to solve complex, large-scale, and time-critical decision problems. “Pascal brings exceptional leadership across mathematical optimization and complementary AI technologies,” said Dr. Oliver Bastert, CTO, Gurobi Optimization. “While mathematical optimization remai
Esri and Pix4D Launch Real-Time Terrestrial Mapping Workflow17.2.2026 14:00:00 CET | Press release
Alliance Brings Seamless Integration of Asset Data into ArcGIS for PIX4Dcatch Users Pix4D joins with Esri to launch new terrestrial scanning workflow for infrastructure-focused organizations. Esri and Pix4D workflow lets field teams capture accurate 3D models and augmented reality using PIX4Dcatch app data integrated directly into ArcGIS Online in real time. New integration enables users to document subsurface assets with seamless precision. Workflow brings high-fidelity, georeferenced documentation and instant verification to the project lifecycle for improved accuracy. Explore the PIX4Dcatch app and publish 3D data to ArcGIS Online. Esri, the global leader in geographic information system (GIS) technology, has launched a terrestrial mapping workflow with Pix4D. A Switzerland-based photogrammetry software company, Pix4D specializes in mobile reality capture and site-digitization. The combined workflow allows field teams to capture and process asset data and manage it within ArcGIS, Es
Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample17.2.2026 14:00:00 CET | Press release
Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, for certain foundational CRISPR-Cas9 intellectual property for use in NGS library preparation. While CRISPR-Cas9 technologies are most commonly associated with their unique ability to find and cut for genome editing, Watchmaker is leveraging it in a fundamentally different way: as a programmable, stoichiometric binding tool to address one of the most persistent and under-optimized steps in NGS workflows – library normalization. “Normalization has quietly become a bottleneck as sequencing throughput has scaled,” said Brian Kudlow, CSO and Founderat Watchmaker Genomics. “This license gives us the freedom to rethink normalization from first principles, using CRISPR-Cas9 in a way that’s orthogonal to editing but highly aligned with modern sequenc
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression17.2.2026 12:30:00 CET | Press release
Two highly statistically significant positive Phase 3 trials confirm highly differentiated profile for COMP360, demonstrating a level of clinical effect that has historically been extremely difficult to achieve in TRDCOMP360 is the first classic psychedelic1 to consistently achieve a highly statistically significant result and clinically meaningful effect, with a generally well-tolerated and safe profileIn COMP006, two doses of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by MADRS2 with a mean difference of -3.8 comparing 25 mg to 1 mg (p<0.001)3Clinically meaningful reduction in MADRS (≥ 25%) observed in significant number of participants in 25mg arm of both trials with 25% in COMP005 and 39% in COMP006Statistically significant rapid onset from the day following administration maintained at all measured timepoints through Week 6 in both clinical trials in the 25 mg armIn COMP005, participa
BeOne Medicines to Present at Upcoming Investor Conferences17.2.2026 12:00:00 CET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at four upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 am ET; Leerink Global Healthcare Conference on Monday, March 9, 2026 at 11:20 am ET; Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 9:35 am ET; and Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 3:00 pm ET Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom